Articles By Jack Cush, MD
Upadacitinib Clinical Efficacy in Psoriatic Arthritis
By Jack Cush, MD
01 April 2021
McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.
Read Article
Inflammatory Conditions Up the Risk of Premature Myocardial Infarction
By Jack Cush, MD
31 March 2021
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Read Article
Aortic Calcification and Lumbar Fracture Risk in Older Men
By Jack Cush, MD
30 March 2021
Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture in older me
Read Article
Hypertension Unaffected by Urate Lowering Therapy
By Jack Cush, MD
30 March 2021
Does uric acid contribute to the risk of hypertension (HTN)? A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).
Read Article
RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)
By Jack Cush, MD
26 March 2021
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Read Article
FDA Panel Rejects Tanezumab for Osteoarthritis
By Jack Cush, MD
25 March 2021
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Read Article
Safety of Paternal DMARD or Biologic Use
By Jack Cush, MD
22 March 2021
A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.
Read Article
RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout
By Jack Cush, MD
22 March 2021
Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.
Read Article
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
By Jack Cush, MD
19 March 2021
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
RheumNow Podcast – Great Associations (3.19.2021)
By Jack Cush, MD
18 March 2021
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Read Article